黄芪甘草汤对慢性非细菌性前列腺炎患者血清IL-6水平及临床效果影响

## 摘要

目的：探讨黄芪甘草汤对慢性非细菌性前列腺炎（CNPC）患者血清白介素-6（IL-6）水平及临床效果的影响。方法：选取2019年1月至2020年12月在本院就诊的60例CNPC患者，随机分为治疗组和对照组各30例。对照组给予常规西医治疗，治疗组在此基础上加用黄芪甘草汤口服，两组均治疗4周。比较两组治疗前后NIH-CPSI评分、血清IL-6水平、总有效率及不良反应发生率。结果：治疗后，两组NIH-CPSI评分均较治疗前明显降低（P<0.05），而治疗组降低幅度更大（P<0.05）；两组血清IL-6水平均较治疗前明显降低（P<0.05），而治疗组降低幅度更大（P<0.05）。治疗组总有效率为86.67%，高于对照组的66.67%（P<0.05）。两组不良反应发生率无统计学差异（P>0.05）。结论：黄芪甘草汤能够有效改善CNPC患者的临床症状，降低血清IL-6水平，提高总有效率，安全性较高，值得临床推广应用。

关键词：黄芪甘草汤；慢性非细菌性前列腺炎；白介素-6；临床效果

## Abstract

Objective: To investigate the effects of Astragalus and Licorice Decoction on serum interleukin-6 (IL-6) level and clinical efficacy in patients with chronic nonbacterial prostatitis (CNPC). Methods: Sixty patients with CNPC who visited our hospital from January 2019 to December 2020 were randomly divided into treatment group and control group, 30 cases in each group. The control group was given conventional western medicine treatment, while the treatment group was given Astragalus and Licorice Decoction orally on this basis. Both groups were treated for 4 weeks. The NIH-CPSI score, serum IL-6 level, total effective rate and adverse reaction rate were compared between the two groups before and after treatment. Results: After treatment, the NIH-CPSI scores of both groups were significantly lower than those before treatment (P<0.05), and the decrease in the treatment group was greater (P<0.05); The serum IL-6 levels of both groups were significantly lower than those before treatment (P<0.05), and the decrease in the treatment group was greater (P<0.05). The total effective rate of the treatment group was 86.67%, higher than that of the control group (66.67%) (P<0.05). The adverse reaction rates of the two groups had no statistical difference (P>0.05). Conclusion: Astragalus and Licorice Decoction can effectively improve the clinical symptoms of CNPC patients, reduce serum IL-6 level, increase total effective rate, and has high safety, which is worthy of clinical promotion and application.

Keywords: Astragalus and Licorice Decoction; chronic nonbacterial prostatitis; interleukin-6; clinical efficacy

## Introduction

Chronic nonbacterial prostatitis (CNPC) is a common disease in urology department, accounting for about 90% of all prostatitis cases ¹. It is characterized by chronic pelvic pain syndrome (CPPS), which includes pain or discomfort in the pelvic region, perineum, lower abdomen, penis or testicles for more than 3 months ². The etiology and pathogenesis of CNPC are not clear yet, but it is generally believed that it is related to immune dysfunction, neuroendocrine disorder, psychological stress and other factors ³. The diagnosis of CNPC mainly depends on clinical symptoms, physical examination and laboratory tests. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) is a widely used tool to evaluate the severity of symptoms and quality of life of CNPC patients .